Group items tagged

nationally designated and highly visible corporate, non-profit, and federal research and development centers or laboratory facilities (hereafter referred to as Center(s)) to Ohio. The Industrial Research and Development Center Program will achieve this goal by enhancing and supplementing Ohio organizations' proposals for such Centers by providing funding that serves as cost share or matching dollars, thereby improving the competitiveness of the proposal and enhancing the potential for a Center being located in Ohio.   The specific goals and objectives of the Industrial Research and Development Center Program are to: ·         Secure new-to-Ohio research and development funding and facilities with "center" designations by their primary sponsor; ·         Increase the reputation and visibility of Ohio within selected fields of research and development that are aligned with Ohio Third Frontier technology focus areas; ·         Provide support for Centers that will conduct applied research, commercialize new technologies and innovations, support Ohio companies and their efforts to launch new, innovative products, and address competitiveness issues of industries that are strategically significant to Ohio. ·         Attract exceptional senior talent from industry and outside Ohio with demonstrated entrepreneurial qualities and attributes that integrates and aligns well to Center-driven, and their own, commercial outcomes and extended talent development; and, ·         Create new, high-tech jobs.

The HPEM Modeling & Effects research and development effort consists of the following areas: understanding the connectivity of infrastructure and mobile targets; understanding the phenomenology of front door effects; developing a predictive effects model; developing a theoretical and empirical basis for HPEM effects ranging from the basic circuit level to the system level effects; empirical effects testing on operational targets as a function of frequency, pulsed duration, and power of the incident HPEM pulse; battle damage assessment; rapid modeling of HPEM system sources and components; improving particle-in-cell code (PIC) capabilities; first principles materials modeling; improving models for electron emission, gas desorption to enhance the predictive capability of virtual prototyping; and developing electromagnetic (EM) algorithms to propagate radio frequency (RF) from platform-specific high power RF systems to targets to assess the performance measures of effective HPEM sources. Sound software engineering and development principles must be employed for all developed software and documentation. Robust software testing, validation, and verification are critical to software development efforts. As appropriate, software must scale to large simulation sizes and be portable to massively parallel computer architecture.

The purpose of this funding opportunity announcement (FOA) is to advance translational research for rare musculoskeletal, rheumatic or skin diseases by supporting preclinical projects conducted by small business concerns (SBCs) to develop biomarkers and/or therapies. The 2010 Institute of Medicine Report "Rare Diseases and Orphan Products: Accelerating Research and Development" (https://www.nap.edu/read/12953/chapter/1) called for active involvement and collaboration by the public and private sectors, and emphasized the role of NIH in integrating various stake holders into a comprehensive strategy for supporting all phases of rare diseases research. NIAMS supports research on rare diseases and orphan drugs through various grant mechanisms including research project grants, center awards and training/career development awards. SBCs play an important role in disease research by developing innovative technologies and increasing the commercial application of federally supported research results. However, it can be more challenging for SBCs to achieve profitability in rare diseases research and development due to inherent scientific risks and market limitations caused by the small number of individuals affected by each disease. With this FOA, NIAMS intends to support and enhance research and development conducted by SBCs that may lead to important biomarkers and/or treatments for rare musculoskeletal, rheumatic or skin diseases.

The RBOG program promotes sustainable economic development in rural communities with exceptional needs through provision of training and technical assistance for business development, entrepreneurs, and economic development officials and to assist with economic development planning. Rural Development is participating in the Investing in Manufacturing Communities Partnership (IMCP), which is a new Administration-wide initiative that will accelerate the resurgence of manufacturing and help cultivate an environment for businesses to create well-paying manufacturing jobs in regions across the country. The IMCP is designed to reward communities that demonstrate best practices in attracting and expanding manufacturing by using long-term planning that integrates targeted investments in workforce training, infrastructure, research, and other key assets. The IMCP is being initiated in FY 2013 as EDA, USDA, SBA and EPA each provide funding for regional implementation strategy grants.

This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support projects devoted to the creation of informative animal models for regenerative medicine, which will facilitate testing the safety and therapeutic potential of animal and human stem cells and their derivatives for pre-clinical evaluation. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cells and their derivatives, including production, characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications. The ultimate objective of these efforts should be to provide commercial products and technologies that can help develop future clinical therapies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support projects devoted to the creation of informative animal models for regenerative medicine, which will facilitate testing the safety and therapeutic potential of animal and human stem cells and their derivatives for pre-clinical evaluation. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cells and their derivatives, including production, characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications. The ultimate objective of these efforts should be to provide commercial products and technologies that can help develop future clinical therapies.

The Instrument Development for Biological Research (IDBR) Program supports the development, production, and distribution of novel instrumentation that addresses demonstrated needs in biological research in areas supported by NSF Biology programs (see http://www.nsf.gov/bio). These systems would benefit a broad user community through mass distribution of the technology. Interdisciplinary collaborations are strongly encouraged, as are partnerships with U.S. industries that can facilitate knowledge transfer, commercialization and broad utilization in the research community. The program accepts two types of proposals:Type A - Innovation: Proposals for the development of novel instrumentation that provides new research capabilities or, where appropriate, that significantly improves current technologies by at least an order of magnitude in fundamental aspects such as accuracy, precision, resolution, throughput, flexibility, breadth of application, costs of construction or operation, or user-friendliness.Type B - Bridging: Proposals for transforming ‘one of a kind' prototypes or high-end instruments into devices that are broadly available and utilizable without loss of capacity. If appropriate, PIs should seek SBIR/STTR Program, or similar support mechanism for implementation of broad distribution following an IDBR award.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

The Thriving Cultures Program supports efforts that provide artists with business training and financial resources that enable them to be, and create, valuable economic assets for their communities. We seek to fund projects that: - Operate business and entrepreneurship training programs for artists and cultural organizations; - Provide financing to artists and artist-centered enterprises (such as financial institutions and resource providers); - Support arts and culture-based programs and services that directly engage and support the people who live and work in the area as a strategy for equitable economic development. These activities may include: 1) Cultural programming; 2) Business incentives that help build the local creative economy; 3) Cross-sector collaborations that yield opportunities for all residents to reap the cultural and economic benefits from neighborhood growth. - Document (both qualitatively and quantitatively) the growth of arts-based, creative industries in neighborhoods; - Identify and share best practices in order to strengthen the field of arts and economic development.

A microenterprise development organization or program (or group or Collaborative thereof) such as a non-profit Community Development Financial Institution or similar entity, that has a demonstrated record of delivering microenterprise services to disadvantaged entrepreneurs or An Intermediary (as defined in Section 8.1) which has experience in delivering technical assistance to disadvantaged entrepreneurs; or A microenterprise development organization or program (as defined in Section 8.1)that is accountable to a local community, working in conjunction with a State or local government or Indian Tribe; or An Indian tribe acting on its own, if it can certify that no private organization or program referred to in paragraph in paragraphs (1) exists within its jurisdiction. Cost Sharing or Matching Requirement: Yes, 50%. Expected Number of Awards: SBA anticipates issuing approximately 35 awards under this Announcement.

The Intermediary must provide a program of financial and technical assistance to recipients to develop their capacity and ability to undertake projects related to housing, community facilities, or community and economic development that will support the community.

This funding opportunity announcement (FOA) is intended to support Small Business Innovation Research (SBIR) grants that develop novel technologies for the purpose of advancing the National Action Alliance for Suicide Prevention's "Zero Suicide" goal of preventing suicide events (attempts, deaths) among individuals receiving treatment within health care systems. Zero Suicide is a commitment to the prevention of suicide among individuals served by health care systems and is also a specific set of health care strategies and tools intended to eliminate suicide events. Research is still needed, however, to implement these goals effectively, and the incorporation of health information technology (health IT) products into this care program is critical. As such, this FOA specifically supports SBIR grants to develop technologies that enable healthcare settings to improve the development, management and/or delivery of services under the Zero Suicide framework.

WHO CAN APPLY? I-Corps@Ohio funds will be offered on a competitive basis to teams of faculty researchers and graduate students developing institution-based technologies from Ohio colleges and universities. Under the supervision of business and entrepreneurial mentors, teams will develop market-driven value propositions and scalable business models around their technologies and attract follow on funding to support company formation and market entry. APPLICATION PROCESS The I-Corps@Ohio proposal submission process consists of five steps: 1. mandatory meeting with the appropriate TTO representative(s) at the PI's institution; 2. team selection of technology track (science and engineering or medtech); 3. registration of all team members in the online portal; 4. proposal submission; and 5. full team interview with I-Corps@Ohio program representatives. All teams are required to complete the online profile and submission questionnaire beginning October 23, 2019. Deadline to apply is January 15, 2019. The PI may complete this information or designate another member of the team as the lead member. Subsequent members of the team will be invited to join by the lead member through the application portal and must complete his or her profile. Every effort should be made to identify all team members prior to submitting the online proposal submission questionnaire. Additional team members may be added later. You will be asked to select from two tracks: Medtech Track: Teams will select Medtech Track if the subject technology is in the form of medical devices, diagnostics, medicines, vaccines, software, testing procedures and systems and is developed to solve a health/clinical problem and improve the quality of human life. Science and Engineering (S&E) Track: Teams will select S&E Track if the technology does not fit into the Medtech category.

I-Corps@Ohio is a statewide program developed to assist faculty, staff and students from Ohio universities, colleges and community colleges in validating the market potential of technologies and launching startup companies. I-Corps@Ohio is modeled after the National Science Foundation's (NSF) successful I-Corps (Innovation Corps) program, which has been proven to increase innovation, entrepreneurship, and industry collaboration. The I-Corps@Ohio program incorporates lean launch, customer discovery and business model innovation methodologies to assess technologies, enhance the business acumen of research faculty and students and expand their entrepreneurial network relationships. Two cohort tracks are offered in Science & Engineering and Medtech, with each designed to offer both common and subject matter specific content. The long-term objective of I-Corps@Ohio is to systematically build a steady and predictable pipeline of  high-quality, high-growth startups from technology developed at the State's colleges, universities, and research institutions, that contribute to economic development in Ohio.

This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions.  The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).  

The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.  Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects.  The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.   

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.  Consistent with the goals of this funding initiative and as required by the SF424 instructions for all Phase II SBIR applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.  

This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Technology Transfer (STTR) projects to develop novel tools and devices to improve handling of laboratory animals, to ease the management of animal facilities, and to enhance experiments which use animal models. The intent is to facilitate the development and implementation of tools and devices to directly benefit the welfare of research animals, and to advance equipment to improve infrastructure and environmental conditions of animal facilities that support biomedical and bio-behavioral research.

Despite the availability of increasingly effective treatment modalities, including insulin analogues, continuous glucose monitors (CGMs), and continuous subcutaneous insulin infusion (CSII) devices, a substantial proportion of patients with type 1 diabetes (T1D) cannot achieve adequate glycemic control and avoid acute complications such as hypoglycemia.  NIDDK has long supported this area of research, especially through small business projects, and this support has contributed substantially to the development of new devices that are increasingly used in clinical practice.  Nonetheless, the approved devices and current technologies still have significant limitations, and it is important to put renewed emphasis on the creation of the next generation of devices that will further the goals of relieving patients of the burden of diabetes self-management and achieving daily euglycemia to prevent acute and chronic complications. However, given the pace of technical progress in this field and the substantial room for improvement in reliability, accuracy, and patient burden of current devices, NIDDK considers it important to continue supporting research in this field. This FOA is intended to support cutting edge research conducted by small business leading to the development of innovative technologies that may advance progress toward an integrated, long term, wearable/implantable, glucose regulated open and closed loop insulin/pancreatic hormone delivery systems.  This announcement has two main purposes: a) promote technical innovation and b) pre-clinical testing of single or combined components of open and closed loop systems

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.